Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NPDR-01
- Development stage
- Phase 1
- Lead developer
- Noppodor
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
NPDR-01 is an experimental ophthalmic solution currently under development for the treatment of non-proliferative diabetic retinopathy (NPDR). Developed by Beijing Nuopuduoer Biopharma Technology, the drug is formulated as an eye drop, offering a potentially non-invasive alternative to intravitreal injections for early-stage diabetic eye disease. NPDR-01 is designed to address diabetic retinal microangiopathy by reducing the formation of microaneurysms and improving retinal lesions. Its primary therapeutic goal is to slow or halt the progression of diabetic retinopathy before it advances to proliferative stages or results in significant vision loss.
Beyond the preview
Go deeper on NPDR-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NPDR-01.